Oncología Médica Traslacional y Terapia Individualizada del Cáncer

Fasching, PA; Slamon, D; Nowecki, Z; Kukielka-Budny, B; Stroyakovskiy, D; Yardley, DA; Huang, CS; Chan, A; Chia, S; Martín, M; Rugo, HS; Loi, S; Hurvitz, S; Untch, M; Afenjar, K; Fresco, R; Danyliv, A; Ferrusi, I; Li, Z; Hortobagyi, G.

Health-Related Quality of Life in Patients with HR+/HER2-Early Breast Cancer Treated with Ribociclib Plus a Nonsteroidal Aromatase Inhibitor: Results from the NATALEE Trial

CLINICAL CANCER RESEARCH. 2025; 31(9): 1625-1635 Nº de citas: 7 [doi:10.1158/1078-0432.CCR-24-1724]

Besse, B; Goto, K; Wang, YS; Lee, SH; Marmarelis, ME; Ohe, Y; Bernabe, R; Kim, DW; Lee, JS; Cousin, S; Ichihara, E; Li, YS; Paz-Ares, L; Ono, A; Sanborn, RE; Watanabe, N; de Miguel, MJ; Helissey, C; Shu, CA; Spira, AI; Tomasini, P; Yang, JCH; Zhang, YP; Felip, E; Griesinger, F; Waqar, SN; Calles, A; Neal, JW; Baik, CS; Jaenne, PA; Shreeve, SM; Curtin, JC; Patel, B; Gormley, M; Lyu, X; Chen, J; Chu, PL; Mahoney, J; Trani, L; Bauml, JM; Thayu, M; Knoblauch, RE; Cho, BC.

Amivantamab Plus Lazertinib in Patients With EGFR-Mutant NSCLC After Progression on Osimertinib and Platinum-Based Chemotherapy: Results From CHRYSALIS-2 Cohort A

Journal of Thoracic Oncology. 2025; 20(5): 651-664 Nº de citas: 23 [doi:10.1016/j.jtho.2024.12.029]

Varela, M; Teixidó, C; Alvarez-Fernández, C; Arasanz, H; Peralta, S; Lázaro, M; Calvo, V; Alvarez, R; Baena, J; Valdivia, J; Arriola, E; Bernabé, R; Isla, D; Camacho, C; Massutí, B; Blasco, A; García, T; Cobo, M; Campayo, M; Hijazo-Pechero, S; Callejo, A; Dominguez, M; Nadal, E.

Prevalence of EGFR gene mutations in patients with early-stage resectable non-small cell lung cancer in Spain: the ORIGEN study

Translational Lung Cancer Research. 2025; 14(4): Nº de citas: 3 [doi:10.21037/tlcr-2024-1146]

Vinuela-Beneitez, MC; Pérez, CI; Morán, LO; Escobar, IG; Lavín, DC; Balanyà, RPI; Adrián, SG; Campos, MC; López, GB; Crespo, JAS; de Mena, ML; Altozano, JP; Díaz, EG; Peces, JT; Rivas, PO; Morales, MJO; Rubio, VEC; Pedroche, CD; Sueiro, MR; Gonçalves, F; Sánchez-Cánovas, M; Ruiz, MA; Muñoz-Langa, J; Segura, PP; de Castro, EM; Carmona-Bayonas, A; Jiménez-Fonseca, P; Martín, AJM.

External validation of a prediction model for bleeding events in anticoagulated cancer patients with venous thromboembolism (PredictAI)

Clinical & Translational Oncology. 2025; : Nº de citas: 1 [doi:10.1007/s12094-025-03890-5]

Valladares-Ayerbes, M; Toledano-Fonseca, M; Graña, B; Jimenez-Fonseca, P; Pulido-Cortijo, G; Gil, S; Sastre, J; Salud, A; Rivera, F; Salgado, M; García-Alfonso, P; López, RL; Guillén-Ponce, C; Rodríguez-Ariza, A; Vieitez, JM; Díaz-Rubio, E; Aranda, E; Spanish Cooperat Grp Treatment Digest Tumours TTD.

Associations of blood RNA biomarkers and circulating tumour cells in patients with previously untreated metastatic colorectal cancer

BMC CANCER. 2025; 25(1): [doi:10.1186/s12885-025-14098-9]

García-Saenz, JA; Spera, G; Pollán, M; Bermejo, B; Ruiz-Borrego, M; Chan, A; Martín, M; Guerrero-Zotano, A; Calvo, L; Rodríguez-Lescure, A; Marín, M; Chap, L; Crown, J; Pienkowski, T; Bee, V; Casas, M; Polonio, O; Bezares, S; Slamon, D.

Body mass index as a predictive factor for efficacy of adjuvant taxane-based chemotherapy in early-stage breast cancer patients: A pooled analysis from adjuvant GEICAM Spanish Breast Cancer Group and TRIO Translational Research in Oncology Group studies

INTERNATIONAL JOURNAL OF CANCER. 2025; 157(4): 709-721 Nº de citas: 2 [doi:10.1002/ijc.35432]

Capdevila, J; Pubul, V; Anido, U; Walter, T; Molina-Cerrillo, J; Alonso-Gordoa, T; Garcia-Carbonero, R; San-Roman-Gil, M; Llana, B; Jimenez-Fonseca, P; Viñuales, MB; Ansquer, C; Baudin, E; Lepage, C; del Olmo-García, M; Ruffinelli, JC; Beron, A; Haissaguerre, M; Deshayes, E; Taïeb, D; Baldari, S; Sansovini, M; Cingarlini, S; Filice, A; Panzuto, F; Alvarez-Alvarez, R; Lousberg, L; Nana, FA; Hernando, J; García-Alvarez, A; García-Burillo, A; Villacampa, G; Vandamme, T; Fazio, N; Durand, A.

A Randomized clinical trial evaluating the impact on survival and quality of life of ¹⁷⁷Lutetium[Lu]-edotreotide versus everolimus in patients with neuroendocrine tumors of the lung and thymus: the LEVEL study (GETNE T-2217)

BMC CANCER. 2025; 25(1): Nº de citas: 3 [doi:10.1186/s12885-025-13941-3]

Galsky, MD; Kockx, M; Roels, J; Van Elzen, R; Guan, XN; Yuen, K; Rishipathak, D; Anker, JF; Gnjatic, S; Izadmehr, S; Sanjabi, S; Johnston, RJ; Peterson, M; Koeppen, H; David, JM; Gupta, S; Bamias, A; Arranz, JA; Kikuchi, E; De Santis, M; Davis, ID; Williams, P; Bernhard, S; Mellman, I; Grande, E; Banchereau, R; Mariathasan, S.

Different PD-L1 Assays Reveal Distinct Immunobiology and Clinical Outcomes in Urothelial Cancer

Cancer Immunology Research. 2025; 13(4): 476-486 Nº de citas: 7 [doi:10.1158/2326-6066.CIR-24-0649]

Alonso-Gonzalo, L; Oblitas, CM; Cebollero-Presmanes, M; Vieru, CM; García-Leoni, ME.

Hepatoid adenocarcinoma of the lung: a rare case report

Galicia Clinica. 2025; 86(2): 27-29 [doi:10.22546/86/2/1272]

Harbeck, N; Dieras, V; Gelmon, KA; Finn, RS; Martin, M; Neven, P; Kim, S; Ma, J; Gauthier, E; Broughton, E; Doan, J; Rugo, HS.

Effect of palbociclib plus letrozole on patient-reported health-related quality of life: extended follow-up of the PALOMA-2 trial

ESMO Open. 2025; 10(4): Nº de citas: 3 [doi:10.1016/j.esmoop.2025.104497]

Giannatempo, P; Machiels, JP; Sassa, N; Arranz, JA; Fujii, Y; Su, WP; Keam, B; Culine, S; Shen, YC; Langa, JM; Sarid, D; Aarts, M; Calabro, F; Rosenbaum, E; Moreno, BH; Bavle, A; Xu, JZ; Rha, SY.

Impact of Histology on Clinical Outcomes of Pembrolizumab Monotherapy in Patients With Advanced or Metastatic Urothelial Carcinoma in the Phase 3 KEYNOTE-045 and KEYNOTE-361 Trials

Clinical Genitourinary Cancer. 2025; 23(2): Nº de citas: 1 [doi:10.1016/j.clgc.2024.102273]

Koshkin VS; Danchaivijitr P; Bae WK; Semenov A; Ozyilkan O; Su YL; Arranz Arija JA; Tsujihata M; Bögemann M; Hendriks MP; Delgado SN; Rosenbaum E; Lopez KA; Bavle A; Liu CC; Imai K; Furka A.

Pembrolizumab Retreatment in Patients with Advanced or Metastatic Urothelial Carcinoma Who Responded to First-course Pembrolizumab-based Therapy.

EUROPEAN UROLOGY. 2025; 87(4): 390-395 Nº de citas: 4 [doi:10.1016/j.eururo.2024.11.012]

Lopez-Tarruella, S; Pollán, M; Carrasco, E; Andrés, R; Martín, M; Servitja, S; Bermejo, B; Antón, A; Guerrero-Zotano, A; Muñoz, M; Fernández, L; del Prado, PM; Alvarez, I; Calvo, L; Rodríguez-Lescure, A; Marín, M; Ruiz-Borrego, M; Herranz, J; Polonio, O; Adrover, E; Moreno, D.

Retrospective analysis to validate the CTS5 in patients from El Álamo IV registry and GEICAM adjuvant studies

ONCOLOGIST. 2025; 30(4): [doi:10.1093/oncolo/oyaf040]

Hahnen, E; Hauke, J; Gelmon, K; Marmé, F; Ernst, C; Martin, M; Untch, M; Bonnefoi, H; Knudsen, E; Im, SA; DeMichele, A; Van't Veer, L; Kim, SB; Bear, H; McCarthy, N; Rhiem, K; Turner, N; Witkiewicz, A; Rojo, F; Filipits, M; Martin, LA; Fasching, PA; Schem, C; Becker, K; García-Sáenz, JA; Kelly, CM; Reimer, T; Toi, M; Rugo, HS; Denkert, C; Gnant, M; Makris, A; Liu, Y; Valota, O; Felder, B; Weber, K; Nekljudova, V; Loibl, S.

BRCA1/2 and Other Predisposition Genes in High-Risk Hormone Receptor plus /Human Epidermal Growth Factor Receptor 2-Breast Cancer Treated With Endocrine Therapy With or Without Palbociclib: A Secondary PENELOPE-B Study Analysis

JCO Precision Oncology. 2025; 9: Nº de citas: 3 [doi:10.1200/PO-24-00742]

Moreno, F; Iranzo, V; Alvarez, I; Antón, A; Chacón, JI; Gavilá, J; Martín, M; Rovira, PS; Gratal, P; González, MJF; López, R.

CDK4/6 inhibitors for metastatic breast cancer in routine clinical practice in Spain: survey of patterns of use and oncologists' perceptions

Clinical & Translational Oncology. 2025; : Nº de citas: 2 [doi:10.1007/s12094-025-03896-z]

Kalinsky, K; Bianchini, G; Hamilton, E; Graff, SL; Park, KH; Jeselsohn, R; Demirci, U; Martin, M; Layman, RM; Hurvitz, SA; Sammons, S; Kaufman, PA; Muñoz, M; Lai, J; Knoderer, H; Sandoval, C; Chawla, AR; Nguyen, B; Zhou, YH; Ravenberg, E; Litchfield, LM; Smyth, L; Wander, SA.

Abemaciclib Plus Fulvestrant in Advanced Breast Cancer After Progression on CDK4/6 Inhibition: Results From the Phase III postMONARCH Trial

JOURNAL OF CLINICAL ONCOLOGY. 2025; 43(9): Nº de citas: 46 [doi:10.1200/JCO-24-02086]

García-Alfonso, P; Valladares-Ayerbes, M; Martín, AJM; Herrero, RM; Muñoz, EG; Prat-Llorens, G.

State of the art of the molecular hyperselection to guide treatment with anti-EGFR antibodies in RAS WT mCRC: implications for clinical practice and future perspectives

EXPERT OPINION ON BIOLOGICAL THERAPY. 2025; 25(4): 413-423 Nº de citas: 2 [doi:10.1080/14712598.2025.2477192]

Sobrero, A; Dasari, A; Aquino, J; Lonardi, S; Garcia-Carbonero, R; Elez, E; Yoshino, T; Yao, J; Garcia-Alfonso, P; Kocsis, J; Gracian, AC; Sartore-Bianchi, A; Satoh, T; Randrian, V; Tomasek, J; Chong, GF; Price, T; Yu, ZJ; Geiger, A; Chen, L; Yang, Z; Schelman, WR; Kania, M; Tabernero, J; Eng, C.

Health-related quality of life associated with fruquintinib in patients with metastatic colorectal cancer: Results from the FRESCO-2 study

EUROPEAN JOURNAL OF CANCER. 2025; 218: Nº de citas: 5 [doi:10.1016/j.ejca.2025.115268]